• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于心肌病的供体细胞移植:它是否能补充当前的药物治疗?

Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies?

作者信息

McMullen Nichole M, Pasumarthi Kishore B S

机构信息

Department of Pharmacology, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Canada.

出版信息

Can J Physiol Pharmacol. 2007 Jan;85(1):1-15. doi: 10.1139/Y06-105.

DOI:10.1139/Y06-105
PMID:17487241
Abstract

Heart failure secondary to ischemic heart disease, hypertension, and myocardial infarction is a common cause of death in developed countries. Although pharmacological therapies are very effective, poor prognosis and shorter life expectancy of heart disease patients clearly indicate the need for alternative interventions to complement the present therapies. Since the progression of heart disease is associated with the loss of myocardial cells, the concept of donor cell transplantation into host myocardium is emerging as an attractive strategy to repopulate the damaged tissue. To this end, a number of donor cell types have been tested for their ability to increase the systolic function of diseased hearts in both experimental and clinical settings. Although initial clinical trials with bone marrow stem cells are encouraging, long-term consequences of such interventions are yet to be rigorously examined. While additional laboratory studies are required to address several issues in this field, there is also a clear need for further characterization of drug interactions with donor cells in these interventions. Here, we provide a brief summary of current pharmacological and cell-based therapies for heart disease. Further, we discuss the potential of various donor cell types in myocardial repair, mechanisms underlying functional improvement in cell-based therapies, as well as potential interactions between pharmacological and cell-based therapies.

摘要

继发于缺血性心脏病、高血压和心肌梗死的心力衰竭是发达国家常见的死亡原因。尽管药物治疗非常有效,但心脏病患者预后不佳且预期寿命较短,这清楚地表明需要替代干预措施来补充现有治疗方法。由于心脏病的进展与心肌细胞的丧失有关,将供体细胞移植到宿主心肌中的概念正成为一种有吸引力的策略,用于修复受损组织。为此,已经在实验和临床环境中测试了多种供体细胞类型增加患病心脏收缩功能的能力。尽管骨髓干细胞的初步临床试验令人鼓舞,但此类干预的长期后果仍有待严格审查。虽然需要更多的实验室研究来解决该领域的几个问题,但在这些干预措施中,也显然需要进一步表征药物与供体细胞的相互作用。在此,我们简要总结了目前用于治疗心脏病的药物疗法和基于细胞的疗法。此外,我们讨论了各种供体细胞类型在心肌修复中的潜力、基于细胞的疗法中功能改善的潜在机制,以及药物疗法和基于细胞的疗法之间的潜在相互作用。

相似文献

1
Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies?用于心肌病的供体细胞移植:它是否能补充当前的药物治疗?
Can J Physiol Pharmacol. 2007 Jan;85(1):1-15. doi: 10.1139/Y06-105.
2
Cell therapy for cardiac repair.用于心脏修复的细胞疗法。
Panminerva Med. 2008 Jun;50(2):129-37.
3
Innovation in basic science: stem cells and their role in the treatment of paediatric cardiac failure--opportunities and challenges.基础科学领域的创新:干细胞及其在小儿心力衰竭治疗中的作用——机遇与挑战
Cardiol Young. 2009 Nov;19 Suppl 2:74-84. doi: 10.1017/S104795110999165X.
4
Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells.另一种用于心脏再生医学的可能的细胞来源:将成纤维细胞重编程为心肌细胞和内皮祖细胞。
Med Hypotheses. 2011 Mar;76(3):365-7. doi: 10.1016/j.mehy.2010.10.041. Epub 2010 Nov 18.
5
Stem cell therapy in cardiovascular disorders.干细胞治疗心血管疾病。
Cardiovasc Ther. 2010 Oct;28(5):e101-10. doi: 10.1111/j.1755-5922.2010.00208.x.
6
Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy-current status and future developments.急性心肌梗死和慢性缺血性心肌病中基于细胞的心血管修复与再生——现状与未来发展
Int J Dev Biol. 2011;55(4-5):407-17. doi: 10.1387/ijdb.103219ct.
7
Stem cells in cardiac repair.心脏修复中的干细胞
Future Cardiol. 2011 Jan;7(1):99-117. doi: 10.2217/fca.10.109.
8
Embryonic and adult stem cell therapy.胚胎和成体干细胞治疗。
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S336-44. doi: 10.1016/j.jaci.2009.09.032. Epub 2010 Jan 12.
9
Stem cells and their potential in cell-based cardiac therapies.干细胞及其在基于细胞的心脏治疗中的潜力。
Prog Cardiovasc Dis. 2007 May-Jun;49(6):396-413. doi: 10.1016/j.pcad.2007.02.006.
10
Stem cell sources for cardiac regeneration.用于心脏再生的干细胞来源。
Panminerva Med. 2008 Mar;50(1):19-30.

引用本文的文献

1
Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury.阿霉素心肌损伤后 FGF1 和 PDGFB 对移植细胞归巢的调节。
Cells. 2021 Nov 3;10(11):2998. doi: 10.3390/cells10112998.
2
Effects of β-adrenergic receptor drugs on embryonic ventricular cell proliferation and differentiation and their impact on donor cell transplantation.β-肾上腺素能受体药物对胚胎心室细胞增殖与分化的影响及其对供体细胞移植的作用。
Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H919-H931. doi: 10.1152/ajpheart.00425.2016. Epub 2017 Mar 10.
3
Somatic cell dedifferentiation/reprogramming for regenerative medicine.
用于再生医学的体细胞去分化/重编程
Int J Stem Cells. 2009 May;2(1):18-27. doi: 10.15283/ijsc.2009.2.1.18.
4
Stem cells: a model for screening, discovery and development of drugs.干细胞:药物筛选、发现与开发的模型
Stem Cells Cloning. 2011 Sep 27;4:51-9. doi: 10.2147/SCCAA.S16417. eCollection 2011.
5
Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies.组织驻留的成体干细胞/祖细胞在移植和癌症治疗中的巨大应用前景。
Adv Exp Med Biol. 2012;741:171-86. doi: 10.1007/978-1-4614-2098-9_12.
6
Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.组织驻留成体干细胞生物学及其治疗意义的最新进展。
Stem Cell Rev. 2008 Spring;4(1):27-49. doi: 10.1007/s12015-008-9008-2.